Breast Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Breast Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 5 (2008), Issue 8 (August)

1. Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy.
   J Clin Oncol, 26(22): 3727-34. [Abstract] [Full-text]
2. Prognostic value of a proliferation index including MIB1 and argyrophilic nucleolar organizer regions proteins in node-negative breast cancer.
   Am J Obstet Gynecol, 199(2): 146.e1-7. [Abstract] [Full-text]
3. SV40 large T antigen-transformed human primary normal and cancerous mammary epithelial cells are phenotypically similar but can be distinguished in 3D culture with selection medium.
   Int J Cancer, 123(7): 1516-25. [Abstract] [Full-text]
4. Do both heterocyclic amines and omega-6 polyunsaturated fatty acids contribute to the incidence of breast cancer in postmenopausal women of the Malmö diet and cancer cohort?
   Int J Cancer, 123(7): 1637-43. [Abstract] [Full-text]
5. Effect of soybean on breast cancer according to receptor status: a case-control study in Japan.
   Int J Cancer, 123(7): 1674-80. [Abstract] [Full-text]
6. Viability analysis and apoptosis induction of breast cancer cells in a microfluidic device: effect of cytostatic drugs.
   Biomed Microdevices, 10(5): 727-37. [Abstract] [Full-text]
7. A novel domain of BRCA1 interacts with p53 in breast cancer cells.
   Cancer Lett, 268(1): 137-45. [Abstract] [Full-text]
8. Anti-tumor activity of N-thiolated beta-lactam antibiotics.
   Cancer Lett, 268(1): 63-9. [Abstract] [Full-text]
9. In-situ monitoring of breast cancer cell (MCF-7) growth and quantification of the cytotoxicity of anticancer drugs fluorouracil and cisplatin.
   Biosens Bioelectron, 24(2): 247-52. [Abstract] [Full-text]
10. Microelectrode chip based real time monitoring of vital MCF-7 mamma carcinoma cells by impedance spectroscopy.
    Biosens Bioelectron, 24(2): 253-9. [Abstract] [Full-text]
11. [18F]FDG and [18F]FLT uptake in human breast cancer cells in relation to the effects of chemotherapy: an in vitro study.
    Br J Cancer, 99(3): 481-7. [Abstract] [Full-text]
12. Target and reality of adjuvant endocrine therapy in postmenopausal patients with invasive breast cancer.
    Br J Cancer, 99(3): 428-33. [Abstract] [Full-text]
13. Effects and potential mechanisms of Danzhi Xiaoyao Pill on proliferation of MCF-7 human breast cancer cells in vitro.
    Chin J Integr Med, 14(2): 128-31. [Abstract] [Full-text]
14. Calmodulin, a regulatory partner of the estrogen receptor alpha in breast cancer cells.
    Mol Cell Endocrinol, 291(1): 20-6. [Abstract] [Full-text]
15. Unraveling the microenvironmental influences on the normal mammary gland and breast cancer.
    Semin Cancer Biol, 18(5): 311-21. [Abstract] [Full-text]
16. Deciphering downstream gene targets of PI3K/mTOR/p70S6K pathway in breast cancer.
    BMC Genomics, 9: 348. [Abstract] [Full-text]
17. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
    J Natl Cancer Inst, 100(15): 1058-67. [Abstract] [Full-text]
18. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain.
    J Natl Cancer Inst, 100(15): 1092-103. [Abstract] [Full-text]
19. Comparing screening mammography for early breast cancer detection in Vermont and Norway.
    J Natl Cancer Inst, 100(15): 1082-91. [Abstract] [Full-text]
20. Mouse embryonic stem cell-based functional assay to evaluate mutations in BRCA2.
    Nat Med, 14(8): 875-81. [Abstract] [Full-text]
21. Physical activity and breast cancer risk: impact of timing, type and dose of activity and population subgroup effects.
    Br J Sports Med, 42(8): 636-47. [Abstract] [Full-text]
22. Pattern of tumor recurrence in initially nonmetastatic breast cancer patients: distribution and frequency of metastases at unusual sites.
    Cancer, 113(4): 677-82. [Abstract] [Full-text]
23. Impact of postmastectomy radiotherapy in T3N0 invasive carcinoma of the breast: a Surveillance, Epidemiology, and End Results database analysis.
    Cancer, 113(4): 683-9. [Abstract] [Full-text]
24. PCDH8, the human homolog of PAPC, is a candidate tumor suppressor of breast cancer.
    Oncogene, 27(34): 4657-65. [Abstract] [Full-text]
25. Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study.
    BMC Cancer, 8: 209. [Abstract] [Full-text]
26. The agreement chart as an alternative to the receiver-operating characteristic curve for diagnostic tests.
    J Clin Epidemiol, 61(9): 866-74. [Abstract] [Full-text]
27. Ethnic variations in mammographic density: a British multiethnic longitudinal study.
    Am J Epidemiol, 168(4): 412-21. [Abstract] [Full-text]
28. Proportion of invasive breast cancer attributable to risk factors modifiable after menopause.
    Am J Epidemiol, 168(4): 404-11. [Abstract] [Full-text]
29. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers.
    Mol Carcinog, 47(9): 701-6. [Abstract] [Full-text]
30. Plasma organochlorine levels and subsequent risk of breast cancer among Japanese women: a nested case-control study.
    Sci Total Environ, 402(2): 176-83. [Abstract] [Full-text]
31. Melatonin down-regulates hTERT expression induced by either natural estrogens (17beta-estradiol) or metalloestrogens (cadmium) in MCF-7 human breast cancer cells.
    Cancer Lett, 268(2): 272-7. [Abstract] [Full-text]
32. Anti-estrogenic effect of unliganded progesterone receptor is estrogen-selective in breast cancer cells MCF-7.
    Cancer Lett, 268(2): 202-11. [Abstract] [Full-text]
33. Decreased production of vascular endothelial growth factor in adriamycin-resistant breast cancer cells.
    Cancer Lett, 268(2): 225-32. [Abstract] [Full-text]
34. A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation.
    J Cell Biol, 182(3): 509-17. [Abstract] [Full-text]
35. Changes in subcellular localisation of MI-ER1 alpha, a novel oestrogen receptor-alpha interacting protein, is associated with breast cancer progression.
    Br J Cancer, 99(4): 639-46. [Abstract] [Full-text]
36. The occurrence of invasive cancers following a diagnosis of breast carcinoma in situ.
    Br J Cancer, 99(4): 611-5. [Abstract] [Full-text]
37. Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram.
    Br J Cancer, 99(4): 616-21. [Abstract] [Full-text]
38. tAnGo: a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer: a prospective pulmonary, cardiac and hepatic function evaluation.
    Br J Cancer, 99(4): 597-603. [Abstract] [Full-text]
39. Using a higher cutoff for the percentage of HER2+ cells decreases interobserver variability in the interpretation of HER2 immunohistochemical analysis.
    Am J Clin Pathol, 130(3): 425-7. [Abstract] [Full-text]
40. Differences and molecular immunohistochemical parameters in the subtypes of infiltrating ductal breast cancer.
    Am J Clin Pathol, 130(3): 414-24. [Abstract] [Full-text]
41. Prognostic impact of marginal adipose tissue invasion in ductal carcinoma of the breast.
    Am J Clin Pathol, 130(3): 382-8. [Abstract] [Full-text]
42. Study of quadrant high-dose intraoperative radiation therapy for early-stage breast cancer.
    Br J Surg, 95(9): 1105-10. [Abstract] [Full-text]
43. The postmastectomy pain syndrome: an epidemiological study on the prevalence of chronic pain after surgery for breast cancer.
    Br J Cancer, 99(4): 604-10. [Abstract] [Full-text]
44. Somatically acquired hypomethylation of IGF2 in breast and colorectal cancer.
    Hum Mol Genet, 17(17): 2633-43. [Abstract] [Full-text]
45. Toker cells of the breast. Morphological and immunohistochemical characterization of 40 cases.
    Hum Pathol, 39(9): 1295-300. [Abstract] [Full-text]
46. Choice and interpretation of statistical tests used when competing risks are present.
    J Clin Oncol, 26(24): 4027-34. [Abstract] [Full-text]
47. Influence of pre- and postdiagnosis physical activity on mortality in breast cancer survivors: the health, eating, activity, and lifestyle study.
    J Clin Oncol, 26(24): 3958-64. [Abstract] [Full-text]
48. Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment.
    J Clin Oncol, 26(24): 3950-7. [Abstract] [Full-text]
49. Psychological reactions, quality of life, and body image after bilateral prophylactic mastectomy in women at high risk for breast cancer: a prospective 1-year follow-up study.
    J Clin Oncol, 26(24): 3943-9. [Abstract] [Full-text]
50. BI-RADS 3, 4, and 5 lesions: value of US in management--follow-up and outcome.
    Radiology, 248(3): 773-81. [Abstract] [Full-text]
51. Human breast cancer tumor models: molecular imaging of drug susceptibility and dosing during HER2/neu-targeted therapy.
    Radiology, 248(3): 925-35. [Abstract] [Full-text]
52. A safe and effective method to implant a totally implantable access port in patients with synchronous bilateral mastectomies: modified femoral vein approach.
    J Surg Oncol, 98(3): 197-9. [Abstract] [Full-text]
53. Residual risk of breast cancer recurrence 5 years after adjuvant therapy.
    J Natl Cancer Inst, 100(16): 1179-83. [Abstract] [Full-text]
54. Glycan microarray of Globo H and related structures for quantitative analysis of breast cancer.
    Proc Natl Acad Sci U S A, 105(33): 11661-6. [Abstract] [Full-text]
55. Expression of Globo H and SSEA3 in breast cancer stem cells and the involvement of fucosyl transferases 1 and 2 in Globo H synthesis.
    Proc Natl Acad Sci U S A, 105(33): 11667-72. [Abstract] [Full-text]
56. Automated breast ultrasound: lesion detection and BI-RADS classification--a pilot study.
    Rofo, 180(9): 804-8. [Abstract] [Full-text]
57. Marginal zone B-cell non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue type: imaging findings.
    AJR Am J Roentgenol, 191(3): 921-30. [Abstract] [Full-text]
58. Pure ductal carcinoma in situ: a range of MRI features.
    AJR Am J Roentgenol, 191(3): 689-99. [Abstract] [Full-text]
59. Role of breast sonography in imaging of adolescents with palpable solid breast masses.
    AJR Am J Roentgenol, 191(3): 659-63. [Abstract] [Full-text]
60. Application of sonographic BI-RADS to synchronous breast nodules detected in patients with breast cancer.
    AJR Am J Roentgenol, 191(3): 653-8. [Abstract] [Full-text]
61. Cortical morphologic features of axillary lymph nodes as a predictor of metastasis in breast cancer: in vitro sonographic study.
    AJR Am J Roentgenol, 191(3): 646-52. [Abstract] [Full-text]
62. Image quality of digital direct flat-panel mammography versus an analog screen-film technique using a low-contrast phantom.
    AJR Am J Roentgenol, 191(3): W80-8. [Abstract] [Full-text]
63. Breast magnetic resonance imaging for preoperative locoregional staging.
    Am J Surg, 196(3): 389-97. [Abstract] [Full-text]
64. Impressive time-related influence of the Dutch screening programme on breast cancer incidence and mortality, 1975-2006.
    Int J Cancer, 123(8): 1929-34. [Abstract] [Full-text]
65. Differential presentation of tumor antigen-derived epitopes by MHC-class I and antigen-positive tumor cells.
    Int J Cancer, 123(8): 1841-7. [Abstract] [Full-text]
66. Genomic copy number alterations as predictive markers of systemic recurrence in breast cancer.
    Int J Cancer, 123(8): 1807-15. [Abstract] [Full-text]
67. Dkk-1 secreted by mesenchymal stem cells inhibits growth of breast cancer cells via depression of Wnt signalling.
    Cancer Lett, 269(1): 67-77. [Abstract] [Full-text]
68. Processing of clustered DNA damage in human breast cancer cells MCF-7 with partial DNA-PKcs deficiency.
    Cancer Lett, 269(1): 174-83. [Abstract] [Full-text]
69. Outcomes of multiple wire localization for larger breast cancers: when can mastectomy be avoided?
    J Am Coll Surg, 207(3): 342-6. [Abstract] [Full-text]
70. AFM indentation study of breast cancer cells.
    Biochem Biophys Res Commun, 374(4): 609-13. [Abstract] [Full-text]
71. Ets2 maintains hTERT gene expression and breast cancer cell proliferation by interacting with c-Myc.
    J Biol Chem, 283(35): 23567-80. [Abstract] [Full-text]
72. Tamoxifen for breast cancer risk reduction: impact of alternative approaches to quality-of-life adjustment on cost-effectiveness analysis.
    Med Care, 46(9): 946-53. [Abstract] [Full-text]
73. Hip bone density predicts breast cancer risk independently of Gail score: results from the Women's Health Initiative.
    Cancer, 113(5): 907-15. [Abstract] [Full-text]
74. Intracystic papillary carcinoma: a review of 917 cases.
    Cancer, 113(5): 916-20. [Abstract] [Full-text]
75. Racial/ethnic differences in adequacy of information and support for women with breast cancer.
    Cancer, 113(5): 1058-67. [Abstract] [Full-text]
76. Clinical experience using hypofractionated radiation schedules in breast cancer.
    Semin Radiat Oncol, 18(4): 257-64. [Abstract] [Full-text]
77. Squalene epoxidase, located on chromosome 8q24.1, is upregulated in 8q+ breast cancer and indicates poor clinical outcome in stage I and II disease.
    Br J Cancer, 99(5): 774-80. [Abstract] [Full-text]
78. Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer.
    Br J Cancer, 99(5): 711-5. [Abstract] [Full-text]
79. Automated telephone follow-up after breast cancer: an acceptability and feasibility pilot study.
    Br J Cancer, 99(5): 704-10. [Abstract] [Full-text]
80. Lymphomas involving the breast: a study of 106 cases comparing localized and disseminated neoplasms.
    Am J Surg Pathol, 32(9): 1299-309. [Abstract] [Full-text]
81. ATP modulates PTEN subcellular localization in multiple cancer cell lines.
    Hum Mol Genet, 17(18): 2877-85. [Abstract] [Full-text]
82. An antimetastatic role for decorin in breast cancer.
    Am J Pathol, 173(3): 844-55. [Abstract] [Full-text]
83. Family history of prostate and breast cancer and the risk of prostate cancer in the PSA era.
    Prostate, 68(14): 1582-91. [Abstract] [Full-text]
84. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.
    Oncogene, 27(37): 5019-32. [Abstract] [Full-text]
85. JunD is involved in the antiproliferative effect of Delta9-tetrahydrocannabinol on human breast cancer cells.
    Oncogene, 27(37): 5033-44. [Abstract] [Full-text]

© 2004-2008 Breast Cancer Research Today. All Rights Reserved.